Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab

Journal of Ovarian Research

Volumn 5, Issue 1, 2012, Pages

  Madsen, Christine Vestergaard ^a,b   Steffensen, Karina Dahl ^a,b   Olsen, Dorte Aalund ^a   Waldstrom, Marianne ^a,b   Smerdel, Maja ^a   Adimi, Parvin ^a   Brandslund, Ivan ^a,b   Jakobsen, Anders ^a,b  

^a LILLEBAELT HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CA 125 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR BB; VASCULOTROPIN; VASCULOTROPIN A;

ADULT; ARTICLE; BRAIN EMBOLISM; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; ILEOVAGINAL FISTULA; IMMUNE FUNCTION TEST; LUMINEX SYSTEM; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SERUM; SIGNAL TRANSDUCTION; TISSUE SECTION; TRANSIENT ISCHEMIC ATTACK; VENOUS THROMBOEMBOLISM;

EID: 84866275588     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-5-23     Document Type: Article

References (39)

1. What is the evidence that tumors are angiogenesis dependent? Folkman J, J Natl Canc Inst 1990 82 4 6 10.1093/jnci/82.1.4 (Pubitemid 20020880)
2. Role of angiogenesis in tumor growth and metastasis. Folkman J, Semin Oncol 2002 29 15 18 12516034
3. Angiogenesis as a therapeutic target. Ferrara N, Kerbel RS, Nature 2005 438 967 974 10.1038/nature04483 16355214 (Pubitemid 43093963)
4. Incorporation of bevacizumab in the primary treatment of ovarian cancer. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX, N Engl J Med 2011 365 2473 2483 10.1056/NEJMoa1104390 22204724
5. A phase 3 trial of bevacizumab in ovarian cancer. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du BA, Sehouli J, Kimmig R, Stahle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM, N Engl J Med 2011 365 2484 2496 10.1056/NEJMoa1103799 22204725
6. OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR, J Clin Oncol 2012 30 2039 2045 10.1200/JCO.2012.42.0505 22529265
7. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI, J Clin Oncol 2007 25 5165 5171 10.1200/JCO.2007.11.5345 18024863 (Pubitemid 350237599)
8. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz HJ, Oza AM, J Clin Oncol 2008 26 76 82 10.1200/JCO.2007.12.1939 18165643
9. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W, J Clin Oncol 2007 25 5180 5186 10.1200/JCO.2007.12.0782 18024865 (Pubitemid 350232248)
10. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) 2012 ASCO Annual Meeting. Oral Abstract Session, Gynecologic Cancer. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote IB, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag DT, Ray-Coquard I, J Clin Oncol 2012 30 suppl bstr LBA5002
11. Clinical biomarkers of angiogenesis inhibition. Brown AP, Citrin DE, Camphausen KA, Cancer Metastasis Rev 2008 27 415 434 10.1007/s10555-008-9143-x 18414993
12. Biomarkers of response and resistance to antiangiogenic therapy. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG, Nat Rev Clin Oncol 2009 6 327 338 10.1038/nrclinonc.2009.63 19483739
13. Predicting benefit from anti-angiogenic agents in malignancy. Jubb AM, Oates AJ, Holden S, Koeppen H, Nat Rev Cancer 2006 6 626 635 10.1038/nrc1946 16837971 (Pubitemid 44140860)
14. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Hefler LA, Zeillinger R, Grimm C, Sood AK, Cheng WF, Gadducci A, Tempfer CB, Reinthaller A, Gynecol Oncol 2006 103 512 517 10.1016/j.ygyno.2006.03.058 16750560 (Pubitemid 44740099)
15. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Cooper BC, Ritchie JM, Broghammer CL, Coffin J, Sorosky JI, Buller RE, Hendrix MJ, Sood AK, Clin Cancer Res 2002 8 3193 3197 12374688 (Pubitemid 35155030)
16. Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer. Oehler MK, Caffier H, Anticancer Res 2000 20 5109 5112 11326678 (Pubitemid 32319090)
17. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Smerdel MP, Steffensen KD, Waldstrom M, Brandslund I, Jakobsen A, Gynecol Oncol 2010 118 167 171 10.1016/j.ygyno.2010. 03.018 20471067
18. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Han ES, Burger RA, Darcy KM, Sill MW, Randall LM, Chase D, Parmakhtiar B, Monk BJ, Greer BE, Connelly P, Degeest K, Fruehauf JP, Gynecol.Oncol 2010 119 484 490 10.1016/j.ygyno.2010.08.016 20870280
19. Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy. Abdollahi A, Folkman J, Drug Resist Updat 2010 13 16 28 10.1016/j.drup.2009.12.001 20061178
20. Biomarkers predicting tumor response and evasion to anti-angiogenic therapy. Jahangiri A, Aghi MK, Biochim Biophys Acta 2012 1825 86 100 22067555
21. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Casanovas O, Hicklin DJ, Bergers G, Hanahan D, Canc Cell 2005 8 299 309 10.1016/j.ccr.2005.09.005 (Pubitemid 41443415)
22. R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. Cao Y, Cao R, Hedlund EM, J Mol Med (Berl) 2008 86 785 789 10.1007/s00109-008-0337-z
23. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M, Cytokine Growth Factor Rev 2005 16 159 178 10.1016/j.cytogfr.2005.01.004 15863032 (Pubitemid 40616114)
24. Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. Abramsson A, Lindblom P, Betsholtz C, J Clin Invest 2003 112 1142 1151 14561699 (Pubitemid 38056291)
25. PDGF and vessel maturation. Hellberg C, Ostman A, Heldin CH, Recent Results Canc Res 2010 180 103 114 10.1007/978-3-540-78281-0-7
26. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Lindahl P, Johansson BR, Leveen P, Betsholtz C, Science 1997 277 242 245 10.1126/science.277.5323.242 9211853 (Pubitemid 27446080)
27. Hallmarks of cancer: interactions with the tumor stroma. Pietras K, Ostman A, Exp Cell Res 2010 316 1324 1331 10.1016/j.yexcr.2010.02.045 20211171
28. VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. Dong J, Grunstein J, Tejada M, Peale F, Frantz G, Liang WC, Bai W, Yu L, Kowalski J, Liang X, Fuh G, Gerber HP, Ferrara N, EMBO J 2004 23 2800 2810 10.1038/sj.emboj.7600289 15229650 (Pubitemid 39013552)
29. Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Huang J, Soffer SZ, Kim ES, McCrudden KW, Huang J, New T, Manley CA, Middlesworth W, O'Toole K, Yamashiro DJ, Kandel JJ, Mol Canc Res 2004 2 36 42 (Pubitemid 38167106)
30. Response Evaluation Criteria In Solid Tumors http://www.eortc.be/recist/ 2012
31. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du BA, Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A, Vermorken J, Int J Gynecol Canc 2011 21 419 423 10.1097/IGC.0b013e3182070f17
32. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf 2009
33. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. Schilder RJ, Sill MW, Lee RB, Shaw TJ, Senterman MK, Klein-Szanto AJ, Miner Z, Vanderhyden BC, J Clin Oncol 2008 26 3418 3425 10.1200/JCO.2007.14.3420 18612157
34. Front-line bevacizumab in serous epithelial ovarian cancer: biomarker analysis of the FINAVAST trial. Karihtala P, Maenpaa J, Turpeenniemi-Hujanen T, Puistola U, Anticancer Res 2010 30 1001 1006 20393027
35. Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer. Inanc M, Er O, Karaca H, Berk V, Ozkan M, Saraymen R, Elmali F, Med Oncol Published online: 12 May 2012
36. Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Brennecke S, Deichmann M, Naeher H, Kurzen H, Melanoma Res 2005 15 515 522 10.1097/00008390-200512000-00006 16314737 (Pubitemid 44124263)
37. Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients. Loven D, Be'ery E, Yerushalmi R, Koren C, Sulkes A, Lavi I, Shaked Y, Fenig E, Acta Oncol 2008 47 104 109 10.1080/02841860701472470 17851858
38. A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. Shin SJ, Jung M, Jeung HC, Kim HR, Rha SY, Roh JK, Chung HC, Ahn JB, Invest New Drugs 2012 30 1501 1510 10.1007/s10637-011-9683-8 21567184
39. Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab. Calleri A, Bono A, Bagnardi V, Quarna J, Mancuso P, Rabascio C, Dellapasqua S, Campagnoli E, Shaked Y, Goldhirsch A, Colleoni M, Bertolini F, Clin Cancer Res 2009 15 7652 7657 10.1158/1078-0432.CCR-09-1493 19996223